Will We Have a Drug for Alzheimer's Disease by 2030? The View From Pharma

S.L. is an employee of Janssen-Cilag Ltd. Within the past 3 years he has performed consultancy for SomaLogic, Eisai, Merck, and Lilly, has held direct grant funding from Astra-Zeneca and EU-funded public-private partnership research funding through IMI with multiple EFPIA companies. He retains an academic position at the University of Oxford, is a founding director of Cristal Health, and is a named inventor on patents for biomarkers held by KCL and the University of Oxford. H.K.M. is an employee of Johnson and Johnson.